Spago Nanomedical receives approval to initiate the clinical trial SPAGOPIX-01
Spago Nanomedical AB (publ) has received approval from the Swedish Medical Products Agency to initiate the first clinical trial with the contrast agent SpagoPix (SN132D) in patients with breast cancer.SpagoPix is a nanomedical contrast agent with potential to significantly improve cancer diagnostics with magnetic resonance imaging (MRI). Spago Nanomedical will initially focus on imaging of breast cancer, a disease that affects approximately 2.1 million people annually. MRI is used regularly for screening, diagnosis, or tumor staging in 15-30% of all breast cancer patients but the need for